Finance

Lists
ALCLS:EPA
Cellectis SA
€0.98
-0.91%
(-0.0090) 1D
Nov 19, 5:35:08 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALCLS...
Open
€0.98
High
€1.00
Low
€0.97
Mkt. cap
64.21M
Avg. vol.
475.69K
Volume
117.58K
52-wk high
€4.75
52-wk low
€0.90
EPS
-€1.15
Shares outstanding
72.09M
No. of employees
227
Open
€0.98
High
€1.00
Low
€0.97
Mkt. cap
64.21M
Avg. vol.
475.69K
Volume
117.58K
52-wk high
€4.75
52-wk low
€0.90
EPS
-€1.15
Shares outstanding
72.09M
No. of employees
227
News stories
From web sources and news partners
Profile
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA
CEOAndré Choulika
Employees227
Founded1999
Headquarters-
SectorHealth Care
IndustryBiotechnology
Last report
Nov 13, 2026
Fiscal period
Q3 2026
- / -
Revenue / Est. (EUR)
4.92M / 13.15M
-62.61%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
12.21M
7.55M
6.90M
5.44M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
24.44M
27.19M
24.98M
56.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.80M
5.59M
5.74M
6.20M
Operating expense
29.56M
32.72M
30.42M
62.95M
Total operating expenses
29.56M
32.72M
30.42M
62.95M
Operating income
-17.35M
-25.17M
-23.52M
-57.51M
Other non operating income
-8.80M
5.90M
2.28M
-3.93M
EBT including unusual items
-26.74M
-17.72M
-21.79M
-61.44M
EBT excluding unusual items
-26.74M
-17.72M
-21.79M
-61.44M
Income tax expense
-423.00K
46.00K
25.00K
30.00K
Effective tax rate
1.58%
-0.26%
-0.11%
-0.05%
Other operating expenses
320.00K
-63.00K
-290.00K
124.00K
Net income
-26.32M
-17.76M
-21.82M
-61.47M
Net profit margin
-215.60%
-235.36%
-316.03%
-1,130.24%
Earnings per share
-0.24
-
-
-
Interest and investment income
2.08M
1.84M
1.55M
-
Interest expense
-2.03M
-1.93M
-2.01M
-
Net interest expenses
44.00K
-83.00K
-468.00K
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.33M
-22.13M
-20.39M
-54.38M
Gain or loss from assets sale
-
-5.00K
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps